Tu Xu

Tu Xu is a seasoned biostatistics professional currently serving as the Director of Biostatistics at Novo Nordisk, leading initiatives in the development of treatments for rare diseases, autoimmune diseases, and oncology, with notable contributions to the approval of Rivfloza in 2023. Prior experience includes roles at Vertex Pharmaceuticals as Associate Director of Biostatistics, where Tu led the CF Clinical Program, and at Agios Pharmaceuticals, focusing on rare diseases. Tu has also held positions at AbbVie, Gilead Sciences, and Amgen, contributing significantly to clinical studies in oncology, as well as providing statistical analysis for pivotal studies and supporting accelerated drug approvals. Educational background includes advanced degrees in statistics and applied mathematics from the University of Illinois at Chicago and Ohio University, with ongoing studies at Harvard Medical School.